Article

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC

2021-11-02

Abstract excerpt

The unavoidable progression of EGFR-mutated NSCLC on EGFR-TKIs forces us to discover solutions for further therapies. Herein, we discuss the necessity of accurate genomic mapping of progressive disease illustrated by a patient case. Tumor rebiopsies at progression are strongly needed to characterize acquired resistance to EGFR-TKI. The necessary data, however, may be reliably obtained only by deep targeted next ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 414992cf-2fa0-5c9e-aa40-c5b27a8a7207
DOI: 10.20944/preprints202111.0052.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLCDOI 10.20944/preprints202111.0052.v1Read

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read

A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.Semantic proximity Read

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Precision oncology for RET-related tumorsSemantic proximity Read

Remarkable response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: A case reportSemantic proximity Read

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.Semantic proximity Read

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read

A comprehensive overview of the relationship between RET gene and tumor occurrenceSemantic proximity Read

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read